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Conclusion: We found that the publication of START A and B 
trials in 2013 substantially increased adoption of HF-WBI for 
breast cancer at KFSYSCC , which increased the use of HF-
WBI by 19-fold. The reimbursement structure allow us to 
quick adopt state of art and standard care for early stage 
breast cancer. 
 
EP-1150  
Patient quality of life treated with IORT during BCS 
followed by whole breast radiotherapy (WBI) 
B. Urbanski
1Greater Poland Cancer Centre, Radiotherapy and 
Gynecological Oncology, Poznan, Poland 
1, A. Roszak1, K. Bratos1, P. Milecki2, A. 
Karczewska-Dzionk2, M. Litoborski3, S. Adamczyk4 
2Greater Poland Cancer Centre, Radiotherapy Ward I, 
Poznan, Poland 
3Candela, Candela, Warsaw, Poland 
4Intra Op, Intra Op, Sunnyvale, USA 
 
Purpose or Objective: The aim of the study was to report 
quality of life and others aspects based on EORTC 
questionnaire intraoperative radiotherapy (IORT) given as a 
boost during breast conserving surgery (BCS) followed by 
adjuvant whole breast radiotherapy (WBRT).  
 
Material and Methods: Between 2008 and 2011 in 150 breast 
cancers patients treated in Greater Poland Cancer Centre. 
Intraoperative radiotherapy as a tumor bed boost was applied 
using mobile electron accelerator Mobetron 1000 (IntraOp 
Medical, Inc.). IORT boost (10 Gy) was followed by 50 Gy 
whole-breast external beam radiotherapy (EBRT). 
Chemotherapy, if indicated, was given before EBRT. The 
observation period was 1,5-5,5 years. The data was assessed 
by EORTC questionnaires (QLQ-C30 and QLQ-BR23) 1 month 
after RT, 6 months, 1 year, 2 years, 3 years and 4 years. 
 
Results : 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tab 1. QLQ-C30 questionnaire data 
 
There was no statistical significance change in quality of life 
in any follow-up period based on Friedman test analysis 
(p=0,2143).  
 
Tab 2. QLQ-BR23 questionnaire data 
 
There was statistical significance change in body image 
between 1 and 6 months after radiation therapy (p=0,008), 
but it was lower than EORTC reference score. Sexual 
enjoyment was lower than EORTC reference score in any 
follow up period time. Systemic therapy side effects was 
higher than EORTC control group in any follow up period 
time. 
 
Conclusion: Intraoperative radiotherapy is proved to be 
tolerable and perspective treatment procedure with no 
statistical significance influence on quality of life. 
